by Dan Roberts
London Eye Hospital Pharma announced today that it has initiated U.S. discussions to gain clinical data for its iolAMD lens system. iolAMD is a novel intraocular lens (IOL) system designed to restore lost vision and provide an independent lifestyle for patients with dry AMD and related diseases. The technology behind the iolAMD lens was inspired by a method used to fix the Hubble Telescope, thus the nickname “Hubble Lens”.
Another device, the Implantable Miniature Telescopcope (IMT), has already been approved in the U.S. to address the problem of central (macular) vision loss. But a device such as the IMT, according to researchers Dr. Bobby Qureshi and Professor Pablo Artal, requires a much larger incision through which the lens is implanted. Another difference between the IMT and the iolAMD is that the IMT magnifies the visual field to encompass the peripheral vision, while the iolAMD redirects the image onto the peripheral retina without significantly magnifying it. Since the peripheral retina, however, does not offer the same clarity as does the macula, acuity with either lens system will be somewhat less than perfect.
Further information about the iolAMD may be found at www.iolAMD.com .
Source: PR Newswire